Lauren Martz

Philadelphia

Executive Director, Biopharma Intelligence at BioCentury

Executive Director, Biopharma Intelligence @BioCentury

Featured in: Favicon

biocentury.com Favicon

friendsofcancerresearch.org Favicon

zephyrnet.com Favicon

harvard.edu

Articles

SMARCA2: The next big opportunity for degraders?

1 week ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentTargeted protein degraders and selective small molecules face off against SMARCA4-mutant cancers at AACR By Lauren Martz, Executive Director, Biopharma IntelligenceNow that targeted protein degraders have achieved clinical validation against established targets, companies are shifting focus to the modality’s primary value proposition: drugging the undruggable.
PTC hits Huntington biomarker, but approval path still uncertain

1 week ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentPlus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more By Lauren Martz, Executive Director of Biopharma Intelligence, Paul Bonanos, Director of Biopharma Intelligence, and Selina Koch, Executive EditorDespite meeting the primary endpoint, new Phase II data from PTC failed to clarify the path to accelerated approval of PTC518 to treat Huntington disease, sending the company’s shares down 19% Monday.
Boehringer raises the bar for oral HER2 inhibitors at AACR 2025

2 weeks ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentAlso in BioCentury’s Clinical Report: CG’s oncolytic virus success, ivonescimab’s latest lung cancer win, and more By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma IntelligenceThe arsenal of therapeutics against HER2 could be on track to expand as selective small molecules raise the bar for efficacy.
Jemperli data create line of sight to organ-sparing in rectal cancer and beyond

2 weeks ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentGSK’s Jemperli leads to sustained clinical complete responses in 95% of rectal cancer patients By Lauren Martz, Executive Director, Biopharma IntelligenceSurgery may soon be displaced as standard of care for certain solid tumors with heavy DNA mutation burdens.
Degraders, bispecifics define translational trends at AACR

3 weeks ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentPlus: New targets involving glycosylation, angiogenesis and more By Lauren Martz, Executive Director, Biopharma IntelligenceBispecific antibodies and targeted protein degraders are front and center at this year’s AACR Annual Meeting, driving modality innovation, while post-translational sugar modifications are emerging as a focal point for new target discovery.
ADC successes in early-line breast cancer via combinations

3 weeks ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentAlso in BioCentury’s Clinical Report: Lilly records an oral GLP-1 win, and new targeted radiotherapy data from Telix By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma IntelligenceThis week’s short list of positive clinical outcomes includes data that brought antibody-drug conjugates two steps closer to their next frontier: combination regimens in frontline cancer treatment. Gilead Sciences Inc.
Verve impresses investors with second shot at PCSK9

1 month ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentIn BioCentury’s Clinical Report, Pfizer and BMS miss out on market opportunities, and more By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma IntelligenceDespite challenging market conditions, at least one biotech saw its share price rise after reporting clinical data this week. A second attempt by Verve Therapeutics Inc.
Reduced animal testing could unlock host of benefits, but not overnight

1 month ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentFDA outlines three-year road map to reduce animal safety studies for mAbs By Lauren Martz, Executive Director, Biopharma Intelligence FDA’s plan to move away from animal tox testing is not new — it’s been decades in the making — but the moment might be right for accelerating progress.
Cartesian's autoimmune CAR T looks durable, Arvinas’ LRRK2 data, and more: Clinical Report

1 month ago | biocentury.com | Lauren Martz

ARTICLE | Product DevelopmentThe week’s gainers and decliners after data readouts By Lauren Martz, Executive Director, Biopharma Intelligence and Paul Bonanos, Director of Biopharma IntelligenceA CAR T cell therapy designed for repeat dosing in autoimmune disease patients has shown durable efficacy after 12 months of follow up. Yet, its maker, Cartesian Therapeutics, like most other companies with positive data this week, got caught up in the market downturn.
The expanding pipeline of VEGF multispecifics

1 month ago | biocentury.com | Lauren Martz

DATA GRAPHICS | Data ByteAt least 35 VEGF multispecific programs are in development By Lauren Martz, Executive Director, Biopharma IntelligenceThe promise of multispecific constructs to improve the therapeutic index of VEGF, while adding to its efficacy via additional targets, has breathed new life into the long-time cancer target. As the industry awaits global Phase III data from the leading bispecific antibody against PD-1 and VEGF — ivonescimab from Akeso Inc.